Sellas Life Sciences Group (SLS)
NASDAQ:SLS
Want to see SLS full AI Analyst Report?
SLS Stock Chart & Stats
$4.11
-$0.10(-9.43%)
At close: 4:00 PM EST
$4.11
-$0.10(-9.43%)
Day’s Range― - ―
52-Week Range$1.39 - $9.51
Previous CloseN/A
Volume1.43M
Average Volume (3M)8.87M
Market Cap
$1.55B
Enterprise Value$1.22B
Total Cash (Recent Filing)$107.20M
Total Debt (Recent Filing)$871.00K
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding186,032,580
10 Day Avg. Volume13,246,717
30 Day Avg. Volume8,869,880
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-51.22
Forecast
1Y Price Target
$10.00Price Target Upside143.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low debt and materially improved equity provide financial flexibility to fund clinical programs and absorb near-term losses. This reduces bankruptcy risk and makes the company a more credible partner for collaborations or non-dilutive funding over the next several months.
Improved Liquidity From Warrant ExercisesRecent warrant exercises meaningfully boosted cash reserves and extended runway, enabling continued clinical development without immediate asset sales. Sustained liquidity supports executing enrollment and data-readout timelines, improving the odds of advancing value-driving trials.
Focused Oncology Immunotherapy PipelineA concentrated pipeline in cancer vaccines/immunotherapies targets high unmet need areas (hematologic malignancies and HER2 cancers). This strategic focus aligns with durable industry tailwinds and enhances partnering/licensing appeal if clinical signals emerge.
Bears Say
No Meaningful RevenueThe absence of a revenue base means the business cannot internally fund operations or scale without external capital. Persistent losses compress returns and force reliance on financing events, making long-term sustainability contingent on trial success or external funding.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow indicate ongoing cash burn tied to R&D and G&A. Continued negative cash generation increases the probability of future financings, which can delay programs or force unfavorable terms, pressuring strategic optionality.
Dilution From Equity-linked FinancingFrequent use of warrant exercises and equity issuance to fund operations dilutes existing shareholders and raises the effective cost of equity capital. Over time this can impair per-share economics, reduce upside for investors, and limit attractiveness of small secondary offerings.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $1.39 and its highest was $9.51 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $1.55B.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.01.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.05.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 186,032,580 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went up 25.096%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (143.31% Upside)
$10.00 (143.31% Upside)
Blogger Sentiment
Neutral
SLS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
399.39%
12-Months-Change
Fundamentals
Return on Equity
-47.12%
Trailing 12-Months
Asset Growth
226.63%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
SLS Stock 12 Month Forecast
Average Price Target
$10.00
▲(143.31% Upside)
Technical Analysis
Galectin Therapeutics
―
Voyager Therapeutics
―
Tiziana Life Sciences
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Ownership Overview
1.22% Insiders
6.32% Mutual Funds
1.96% Other Institutional Investors
78.51% Public Companies and Individual Investors